Assessing developability early in the discovery process for novel biologics

Author:

Fernández-Quintero Monica L.1ORCID,Ljungars Anne2ORCID,Waibl Franz1ORCID,Greiff Victor3ORCID,Andersen Jan Terje45ORCID,Gjølberg Torleif T.6ORCID,Jenkins Timothy P.2ORCID,Voldborg Bjørn Gunnar7ORCID,Grav Lise Marie2ORCID,Kumar Sandeep8ORCID,Georges Guy9ORCID,Kettenberger Hubert9ORCID,Liedl Klaus R.1ORCID,Tessier Peter M.10ORCID,McCafferty John1112ORCID,Laustsen Andreas H.2ORCID

Affiliation:

1. Center for Molecular Biosciences Innsbruck (CMBI), Department of General, Inorganic and Theoretical Chemistry, University of Innsbruck, Innsbruck, Austria

2. Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark

3. Department of Immunology, University of Oslo, Oslo, Norway

4. Department of Immunology, University of Oslo, Oslo University Hospital Rikshospitalet, Oslo, Norway

5. Institute of Clinical Medicine and Department of Pharmacology, University of Oslo, Oslo, Norway

6. Authera AS, Oslo Science Park, Oslo, Norway

7. National Biologics Facility, Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark

8. Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA

9. Roche Pharma Research and Early Development, Large Molecule Research, Roche Innovation Center Munich, Penzberg, Germany

10. Department of Chemical Engineering, Pharmaceutical Sciences and Biomedical Engineering, Biointerfaces Institute, University of Michigan, Ann Arbor, Michigan, USA

11. Department of Medicine, Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK

12. Maxion Therapeutics, Babraham Research Campus, Cambridge, UK

Funder

the European Research Council

Horizon 2020

UiO World-Leading Research Community

Norwegian Cancer Society

Austrian Academy of Sciences

Novo Nordisk Foundation

National Institutes of Health

National Science Foundation

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3